Amylase
U/L
Metabolic
Optimal Range
30 - 110 U/L
Max
The pancreas plays a dual role — producing digestive enzymes and regulating blood sugar through insulin. This panel measures enzymes like amylase and lipase that indicate how well your pancreas is functioning.
The pancreas is a dual-function organ uniquely responsible for two of the most vital processes in human physiology: digestion and blood sugar regulation. Its exocrine function (95% of pancreatic tissue) produces digestive enzymes — lipase for fat, amylase for starch, proteases for protein — that are secreted into the small intestine. Its endocrine function (the islets of Langerhans) produces insulin, glucagon, somatostatin, and pancreatic polypeptide, which collectively regulate blood glucose and coordinate the metabolic response to feeding.
When the pancreas becomes inflamed — through gallstones, alcohol, or other triggers — enzyme activation within the gland itself causes auto-digestion, a painful and potentially life-threatening condition called pancreatitis. Blood levels of lipase and amylase, which leak from damaged acinar cells, are the primary diagnostic markers. Understanding pancreatic health through regular testing is particularly important given the pancreas's dual role: exocrine insufficiency causes malnutrition through impaired fat digestion, while endocrine dysfunction produces diabetes — both preventable if caught early.
Pancreas health does not exist in isolation — it is deeply intertwined with every major system.
The pancreatic duct and common bile duct converge at the ampulla of Vater before emptying into the duodenum. This anatomical junction explains why gallstones that migrate to the ampulla simultaneously obstruct bile flow and pancreatic secretion, causing the classic presentation of gallstone pancreatitis with elevated liver enzymes and pancreatic enzymes together. Pancreatic cancer often presents with jaundice from biliary compression before other symptoms, and elevated bilirubin with elevated CA 19-9 in the appropriate context is a key diagnostic combination.
The pancreatic beta cells are the body's sole source of insulin — the hormone without which cells cannot take up glucose and life becomes incompatible within days. Autoimmune destruction of beta cells (type 1 diabetes) or progressive beta cell exhaustion from chronic insulin resistance (type 2 diabetes) both impair this function. Pancreatogenic diabetes (type 3c) results from structural pancreatic damage — from chronic pancreatitis, cystic fibrosis, or pancreatectomy — and has distinct management challenges. C-peptide, the cleavage product of proinsulin, directly measures endogenous insulin secretion capacity.
Exocrine pancreatic insufficiency (EPI) — reduced secretion of digestive enzymes — causes malabsorption of fats, fat-soluble vitamins (A, D, E, K), and proteins. Chronic pancreatitis is the most common cause in adults; cystic fibrosis is the most common cause in children. Unrecognised EPI causes steatorrhoea (fatty, floating stools), weight loss, and micronutrient deficiency despite adequate food intake. Faecal elastase-1 is the standard non-invasive screening test for EPI; low fecal elastase below 200 µg/g warrants pancreatic enzyme replacement therapy.
Autoimmune pancreatitis (AIP) is an increasingly recognised form of pancreatitis caused by IgG4-secreting plasma cells infiltrating the pancreas, often producing elevated serum IgG4. Type 1 AIP is a systemic IgG4-related disease affecting pancreas, bile ducts, kidneys, and lacrimal glands simultaneously. It mimics pancreatic cancer on imaging but responds dramatically to corticosteroids — making accurate immunological diagnosis critical to avoid unnecessary pancreatectomy. Elevated IgG4 above 135 mg/dL is the diagnostic threshold, though sensitivity is only 60–70%.
Clinical Note
Lipase is preferred over amylase for diagnosing acute pancreatitis — it is more sensitive, more specific, and remains elevated longer. A lipase level three or more times the upper normal limit with compatible abdominal pain is diagnostic. However, lipase can be mildly elevated in non-pancreatic conditions including renal failure, intestinal ischaemia, and macrolipasaemia. Clinical context is always required for accurate interpretation.
Amylase and lipase are digestive enzymes produced by the pancreas and released into the small intestine to break down carbohydrates and fats. When the pancreas is inflamed (pancreatitis), these enzymes leak into the bloodstream in abnormally high quantities. Serum lipase is the preferred marker for acute pancreatitis — it rises earlier, stays elevated longer, and is more specific than amylase. A lipase level three or more times above the upper normal limit, combined with abdominal pain, is the diagnostic threshold for acute pancreatitis. Amylase is also produced by salivary glands, making it less specific for pancreatic disease.
The two most common causes of elevated lipase and amylase are gallstones (gallstone pancreatitis) and excessive alcohol consumption, which together account for about 80% of acute pancreatitis cases. Other causes include certain medications (corticosteroids, azathioprine, didanosine), hypertriglyceridaemia (triglycerides above 1,000 mg/dL), hypercalcaemia, abdominal trauma, and autoimmune pancreatitis. Mildly elevated amylase without symptoms is often caused by salivary gland inflammation, kidney disease (reduced enzyme clearance), or macroamylasaemia — a benign condition.
Acute pancreatitis is a sudden inflammatory episode characterised by severe upper abdominal pain, elevated blood enzymes, and often requires hospitalisation. Most cases resolve completely within a week. Chronic pancreatitis is a progressive, irreversible destruction of pancreatic tissue — typically from recurrent acute episodes or long-term alcohol use. In chronic pancreatitis, enzyme levels may be normal or low because the gland has lost enough function. Chronic pancreatitis leads to exocrine insufficiency (poor fat digestion, steatorrhoea), endocrine insufficiency (pancreatogenic diabetes), and significantly elevated pancreatic cancer risk.
Currently, no blood test is reliable enough for routine pancreatic cancer screening in the general population. CA 19-9 is the most commonly used tumour marker for pancreatic cancer, but it has poor sensitivity for early-stage disease (only 50–60% sensitivity at Stage I/II) and can be elevated by benign biliary conditions, liver disease, and other GI cancers. CA 19-9 is primarily useful for monitoring treatment response and detecting recurrence in diagnosed patients. Elevated lipase with unexplained weight loss and back pain warrants imaging — not reliance on blood markers alone.
The most important protective factors are alcohol moderation (heavy alcohol use is the leading preventable cause of both acute and chronic pancreatitis), maintaining healthy triglycerides below 150 mg/dL through reduced sugar and refined carbohydrate intake, and preventing or managing gallstones through healthy weight and diet. Smoking doubles the risk of both pancreatitis and pancreatic cancer. A diet rich in vegetables, legumes, and whole grains with limited processed meats is associated with lower pancreatic cancer incidence in large prospective studies.
Join thousands who have discovered their health optimization opportunities through comprehensive pancreas testing.